**Supplementary Table 3. Densities of FoxP3+ and CD3+ TILs in validation set (161 stage II CRC), by clinical-pathological variables.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **FoxP3+TILs** **IRA%** |  | **CD3+TILs** **IRA%** |
|  | n | (%) |  | median | 2nd-3rd quartile | pa |  | median | 2nd-3rd quartile | pa |
|  |  |  |  |  |  |  |  |  |  |  |
| **ALL CASES** b | 161 | (100) |  | 0.27 | 0.11-0.51 | - |  | 2.34 | 1.19-4.59 | - |
|  |  |  |  |  |  |  |  |  |  |  |
| **PATIENT DEMOGRAPHICS** |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Age at Diagnosis** | ≥ 70 yrs. | 91 | (56.5) |  | 0.28 | 0.11-0.48 |  |  | 2.15 | 1.15-4.48 |  |
| < 70 yrs. | 70 | (43.5) |  | 0.24 | 0.11-0.79 | .60 |  | 2.57 | 1.26-5.56 | .35 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Gender** | male  | 94 | (58.4) |  | 0.27 | 0.07-0.49 |  |  | 2.28 | 1.15-4.54 |  |
| female | 67 | (41.6) |  | 0.28 | 0.13-0.51 | .44 |  | 2.42 | 1.26-5.00 | .99 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **TUMOR FEATURES** |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Site** c | proximal | 81 | (50.6) |  | 0.25 | 0.11-0.51 |  |  | 2.21 | 1.35-4.66 |  |
| distal | 79 | (49.4) |  | 0.31 | 0.10-0.49 | .85 |  | 2.36 | 1.05-4.51 | .62 |
|  |  |  |  |  |  |  |  |  |  |  |
| **Local Invasion** | pT3 | 150 | (93.2) |  | 0.27 | 0.11-0.49 |  |  | 2.33 | 1.48-4.54 |  |
| pT4 | 11 | (6.8) |  | 0.33 | 0.50-1.31 | .41 |  | 3.36 | 1.84-6.74 | .20 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Grade** d | G1/G2 | 146 | (92.4) |  | 0.27 | 0.10-0.49 |  |  | 2.16 | 1.19-4.49 |  |
| G3 | 12 | (7.6) |  | 0.31 | 0.09-0.79 | .62 |  | 3.05 | 0.92-6.09 | .64 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Cell Type** | adenocarcinoma | 152 | (94.4) |  | 0.26 | 0.11-0.51 |  |  | 2.39 | 1.17-4.62 |  |
| variants e | 9 | (5.6) |  | 0.28 | 0.25-0.33 | .93 |  | 1.67 | 1.42-2.37 | .53 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Angio-invasion** | No | 134 | (83.2) |  | 0.26 | 0.10-0.51 |  |  | 2.43 | 1.27-5.18 |  |
| Yes | 27 | (16.8) |  | 0.31 | 0.13-0.46 | .99 |  | 1.84 | 0.96-2.91 | .17 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| a at Wilcoxon/Mann-Whitney testb each tumor staged by at least 12 negative nodes and preliminary tested for MS-status; MSI CRC excludedc to splenic flexure; not assessable in 1 cased G1/G2, well-to moderately differentiated cancers; G3, poorly differentiated; not assessable in 3 casese mucinous histology, signet ring, or medullary type |